RxDoctor Payments Data

Sriram Padmanabhan, MD

Cardiovascular Disease · Baltimore, MDNPI 1649265034

Payments from drug & device makers

$18,817in general payments, 2019–2025

Across 29 payments — averaging $648.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$18K
  • Boston Scientific$142
  • Atricure, Inc.$129
  • E.r. Squibb & Sons, L.L.C.$123
  • Scpharmaceuticals Inc.$121
  • Janssen Scientific Affairs, LLC$98
  • plus $277 from 4 others

What the payments were for

  • Speaking & faculty fees$17,35092%
  • Food & beverage$1,4588%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,817 in reported general payments places this provider in the 80th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$392,514
Medicare patients
2,326
Services billed
5,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$278,641
XareltoRivaroxaban133$168,887
EntrestoSacubitril/Valsartan94$118,964
JardianceEmpagliflozin48$67,223
Repatha SureclickEvolocumab27$39,343
VascepaIcosapent Ethyl31$26,577
BrilintaTicagrelor20$23,325
Repatha PushtronexEvolocumab20$22,433
Praluent PenAlirocumab29$20,586
Repatha SyringeEvolocumab14$20,173
Rosuvastatin Calcium373$11,824
Metoprolol Succinate629$10,156
Ezetimibe170$7,820
Icosapent Ethyl20$6,448
Atorvastatin Calcium439$5,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$97$168,887133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →